Solid Biosciences Inc. (NASDAQ:SLDB) Stock Has Consensus Target Price of $18.79 According to Brokerages

Posted by George Bondi on Nov 6th, 2026

Solid Biosciences Inc. (NASDAQ:SLDB – Get Free Report) has been given a consensus rating of “Moderate Buy” by the thirteen ratings firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $20.00.

A number of research analysts recently weighed in on the stock. Loop Capital set a $25.00 target price on shares of Solid Biosciences in a report on Monday, September 14th. Royal Bank Of Canada began coverage on shares of Solid Biosciences in a research report on Wednesday, September 16th. They issued an “outperform” rating and a $18.00 price target on the stock. Truist Financial upped their price target on shares of Solid Biosciences from $16.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, August 21st. UBS Group initiated coverage on shares of Solid Biosciences in a research report on Wednesday, October 14th. They set a “buy” rating and a $20.00 price objective for the company. Finally, Cantor Fitzgerald lifted their price objective on shares of Solid Biosciences from $16.00 to $26.00 and gave the stock an “overweight” rating in a research note on Thursday, August 27th.

Read Our Latest Analysis on SLDB

Solid Biosciences Price Performance

Shares of Solid Biosciences stock opened at $6.18 on Tuesday. The stock has a 50 day moving average of $7.55 and a 200 day moving average of $7.66. Solid Biosciences has a 12 month low of $3.79 and a 12 month high of $11.45.

Solid Biosciences (NASDAQ:SLDB – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.05. As a group, analysts forecast that Solid Biosciences will post -1.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in SLDB. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Solid Biosciences in the 3rd quarter worth approximately $40,000. China Universal Asset Management Co. Ltd. increased its position in shares of Solid Biosciences by 24.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,564 shares of the company’s stock valued at $140,000 after purchasing an additional 3,896 shares during the last quarter. AXQ Capital LP bought a new position in shares of Solid Biosciences during the 2nd quarter valued at approximately $197,000. Engineers Gate Manager LP raised its holdings in Solid Biosciences by 34.5% during the 2nd quarter. Engineers Gate Manager LP now owns 28,915 shares of the company’s stock valued at $289,000 after buying an additional 7,410 shares during the period. Finally, Hsbc Holdings PLC raised its holdings in Solid Biosciences by 78.4% during the 1st quarter. Hsbc Holdings PLC now owns 39,511 shares of the company’s stock valued at $284,000 after buying an additional 17,360 shares during the period. Institutional investors own 81.46% of the company’s stock.

Solid Biosciences Company Profile

(Get Free Report)

Solid Biosciences Inc (NASDAQ: SLDB) is a biotechnology company focused on developing gene therapies for neuromuscular and other serious genetic diseases. The company uses adeno-associated virus (AAV) delivery technologies and genetic medicine approaches to develop treatments intended to address the underlying causes of disease.

Its lead investigational program, SGT-003, is being developed as a gene therapy for Duchenne muscular dystrophy, a severe X-linked muscle-wasting disorder. Solid Biosciences also has additional preclinical and clinical programs targeting other neuromuscular conditions, including diseases associated with defects in muscle proteins.